Informazioni generali
  • Categoria della malattia Lesione / ferita , Altro (BASEC)
  • Fase dello studio Phase 1/Phase 2 (ICTRP)
  • Stato di reclutamento reclutamento non ancora iniziato (BASEC/ICTRP)
  • Luogo dello studio
    Losanna
    (BASEC)
  • Responsabile dello studio Dr Anthony De Buys Roessingh anthony.debuys-roessingh@chuv.ch (BASEC)
  • Fonte dati BASEC: Importato da 02.06.2025 ICTRP: Importato da 18.01.2024
  • Ultimo aggiornamento 02.06.2025 10:56
HumRes58777 | SNCTP000004957 | BASEC2020-01873 | NCT05339490

Evaluation of the safety and efficacy of biological dressings for burn care.

  • Categoria della malattia Lesione / ferita , Altro (BASEC)
  • Fase dello studio Phase 1/Phase 2 (ICTRP)
  • Stato di reclutamento reclutamento non ancora iniziato (BASEC/ICTRP)
  • Luogo dello studio
    Losanna
    (BASEC)
  • Responsabile dello studio Dr Anthony De Buys Roessingh anthony.debuys-roessingh@chuv.ch (BASEC)
  • Fonte dati BASEC: Importato da 02.06.2025 ICTRP: Importato da 18.01.2024
  • Ultimo aggiornamento 02.06.2025 10:56

Descrizione riassuntiva dello studio

The main objective of this study is to demonstrate the effectiveness of the treatment of the donor site for grafting (DSW) with PBB compared to standard treatment (Jelonet®), while the secondary objectives are to evaluate the effectiveness of DSW treatment in the short and long term, and to collect observational data on 2nd degree burns treated with PBB as first-line treatment. Additionally, another objective of this study is to confirm the safety of using PBB on DSW wounds and 2nd degree burns. The ultimate goal is to implement this specific cell therapy for acute wounds such as burns within the CHUV and in accordance with the changes to the transplantation law of 2007.

(BASEC)

Intervento studiato

Patients who will be candidates for autologous skin grafting (with 3rd degree burns or 2nd degree burns that do not close after treatment with PBB) and for whom a donor site wound will be created, will be randomized between a group treated with PBB and a control group treated with standard dressings (Jelonet®), in order to compare the effectiveness of treatment on the healing of the donor site between the two types of dressings. As soon as the donor site wound is created, PBB or Jelonet® will be applied directly to the wound and held in place with standard bandages for a maximum of 15 ± 1 days with dressing changes on day 5 ± 1 and day 10 ± 1. Photographs will be taken at each dressing change and an on-site assessment of healing (% re-epithelialization) will be performed by the operator. If the DSW is not closed by J15 ± 1, Jelonet® will be used to cover the skin until complete closure. If the wound closes after 15 ± 1 days or earlier, the scar will then be treated locally with cream as standard treatment. All patients will be followed up to 5 years according to the long-term evaluation schedule to monitor long-term skin quality. Patients with 2nd degree burns will be treated primarily with PBB which will be applied directly to the 2nd degree burn and held in place with standard bandages for a maximum of 10 to 12 days with dressing changes every 2 to 3 days. Photographs will be taken at each dressing change and an on-site assessment of healing (% re-epithelialization) will be performed by the operator. If the 2nd degree burn is not closed by J10-12, an autologous skin graft will be planned and the treatment of the donor site will be decided by randomization between PBB or Jelonet®. If the wound closes after 10 to 12 days, the scar will then be treated locally with cream as standard treatment. All patients will be followed up to 5 years according to the long-term evaluation schedule to monitor long-term skin quality.

(BASEC)

Malattie studiate

The skin, as the outermost organ of the human body, serves as a protective layer against microorganisms and external forces, and allows for the control of fluid loss among other important functions (sensory, immune, and aesthetic functions). When the skin is burned, the extent of depth can be classified into 1st, 2nd superficial to deep, 3rd and 4th degrees, depending on the different layers of skin and tissue that are affected in depth. The severity of a burn can also be characterized by the total body surface area burned (TBSA), the location of the burn, the characteristics of the subject, and their age. The standard treatment for 3rd or deep 2nd degree burns is autologous skin grafting, which means the transplantation of healthy skin taken from an intact donor site of the patient to the burned site, thereby creating a wound at the donor site. The Burn Center of CHUV has developed biological dressings (PBB), composed of human skin progenitor cells (stored as clinical cell banks produced according to Good Manufacturing Practices and stored by the cell production center (CPC) accredited by CHUV). These cells are ready to use and can be seeded onto a biodegradable collagen support (Resorba®), which is applied directly to the wounds to promote healing of the donor site of the graft, as well as 2nd degree burns. PBB has been applied at CHUV in accordance with emergency medicine over the past 20 years in children and adults with a burned body surface area greater than 10% and 20%, respectively. These PBB aim to improve the spontaneous healing of superficial and deep 2nd degree burns, to avoid autologous skin grafting, and thus prevent the creation of a second wound at the donor site. Furthermore, if autologous skin grafting cannot be avoided, in the case of 3rd or deep 2nd degree burns that do not close spontaneously, the use of PBB is an advantage for the treatment of the donor site wound to accelerate its healing process and be able to reuse the same donor site for subsequent treatments.

(BASEC)

Criteri di partecipazione
• Pediatric patients of either sex ≤ 2 years with ≥ 5% TBSA, or 3 to 10 years with ≥ 10% TBSA, or 11 to 18 years with ≥ 15% TBSA • Adult patients of either sex ≥ 18 years with ≥ 20% TBSA or ≥ 65 years with ≥ 10% TBSA • Patients with 2nd degree burns (superficial to deep) and/or 3rd degree burns candidates for autologous skin grafting (BASEC)

Criteri di esclusione
• Infected wounds • Hemodynamic instability due to burn shock • Known allergy or hypersensitivity to an equine-derived product (BASEC)

Luogo dello studio

Losanna

(BASEC)

non disponibile

Sponsor

University Hospital CHUV

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

Dr Anthony De Buys Roessingh

+41 79 556 37 67

anthony.debuys-roessingh@chuv.ch

University Hospital CHUV

(BASEC)

Informazioni generali

Lausanne Burn Center, Lausanne University Hospital CHUV

(ICTRP)

Informazioni scientifiche

+41 21 314 30 70

anthony.debuys-roessingh@chuv.ch

(ICTRP)

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione d'etica Vaud

(BASEC)

Data di approvazione del comitato etico

15.12.2020

(BASEC)


ID di studio ICTRP
NCT05339490 (ICTRP)

Titolo ufficiale (approvato dal comitato etico)
Evaluation of the safety and effectiveness of Progenitor Biological Bandages in burn care. (BASEC)

Titolo accademico
Evaluation of the Safety and Effectiveness of Progenitor Biological Bandages in Burn Care (ICTRP)

Titolo pubblico
Use of Progenitor Biological Bandages in Burn Care (Bru_PBB) (ICTRP)

Malattie studiate
Burn Injury
(ICTRP)

Intervento studiato
Device: Jelonet
Drug: Progenitor Biological Bandages
(ICTRP)

Tipo di studio
Interventional (ICTRP)

Disegno dello studio
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). (ICTRP)

Criteri di inclusione/esclusione

Inclusion Criteria:

- = 2 years old with =5% TBSA

- between 3 and 10 years old with =10% TBSA

- between 11 and 18 years old with =15% TBSA

- = 18 years old with = 20% TBSA

- = 65 years old with = 10% TBSA

- Any age with burns on the face, hands, genitalia or major joints

- Patient with 2nd (superficial to deep) degree burn wounds

- Patient with 3rd degree burns candidate for a skin autograft

- Informed Consent as documented by signature and according to consent in case of
emergency situation

- First injury

- Possibility of Follow-up for 5 years after injury

Exclusion Criteria:

- Infected wounds

- Vitally unstable patients

- Known allergy or hypersensitivity to product of equine origin

- Refusal of the study by the participants or relatives
(ICTRP)

non disponibile

Endpoint primari e secondari
Wound re-epithelialization assessment at Day 10
(ICTRP)

Long-term skin quality - Scar colour
Short-term efficacy of treatment
Long-term skin quality - Scar appearance (Vancouver Scar Scale)
Long-term skin quality - Elastography
(ICTRP)

Data di registrazione
04.04.2022 (ICTRP)

Inclusione del primo partecipante
01.01.2024 (ICTRP)

Sponsor secondari
non disponibile

Contatti aggiuntivi
Anthony De Buys Roessingh, Lausanne Burn Center, Lausanne University Hospital CHUV (ICTRP)

ID secondari
RA10106, 2020-01873, 2020TpP1010 (ICTRP)

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05339490 (ICTRP)

Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile